Cargando…
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC),...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/ https://www.ncbi.nlm.nih.gov/pubmed/31693178 http://dx.doi.org/10.1002/jcp.29371 |
_version_ | 1783498965767946240 |
---|---|
author | Wang, Chengdi Qiao, Wenliang Jiang, Yuting Zhu, Min Shao, Jun Wang, Tao Liu, Dan Li, Weimin |
author_facet | Wang, Chengdi Qiao, Wenliang Jiang, Yuting Zhu, Min Shao, Jun Wang, Tao Liu, Dan Li, Weimin |
author_sort | Wang, Chengdi |
collection | PubMed |
description | BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC), but it remains unanswered which is superior. The current study aimed to estimate the comparative efficacy and safety of ICI‐chemotherapy versus ICI‐monotherapy in advanced NSCLC. METHODS: Studies were identified by searching PubMed, Embase, and Cochrane library. The randomized controlled trials (RCTs) that ICI monotherapy or ICI plus chemotherapy compared with chemotherapy in NSCLC were included with available primary endpoints of progression‐free survival (PFS), overall survival (OS), objective response rate, or treatment‐related adverse events. A fixed‐effect or random‐effects model was adopted depending on between‐study heterogeneity. RESULTS: A total of 20 RCTs involving 12,025 patients with NSCLC were included. Both ICI‐monotherapy and ICI‐chemotherapy resulted in significantly prolonged survival compared to chemotherapy and the former led to significantly longer PFS. The magnitude of survival benefits appeared to be greatest among those treated with pembrolizumab plus platinum‐based chemotherapy (OS, 0.56; PFS, 0.54). Additionally, OS and PFS advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD‐L1) expression level, but not in intermediate PD‐L1 TPS. CONCLUSIONS: Pembrolizumab plus platinum‐based chemotherapy was recommended as the optimal first‐line therapy for advanced patients with NSCLC. Additionally, PD‐L1 alone is not recommended as an adequate molecular biomarker to identify eligible patients for routine clinical practice in immunotherapy. |
format | Online Article Text |
id | pubmed-7028135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70281352020-02-25 The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis Wang, Chengdi Qiao, Wenliang Jiang, Yuting Zhu, Min Shao, Jun Wang, Tao Liu, Dan Li, Weimin J Cell Physiol Original Research Articles BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC), but it remains unanswered which is superior. The current study aimed to estimate the comparative efficacy and safety of ICI‐chemotherapy versus ICI‐monotherapy in advanced NSCLC. METHODS: Studies were identified by searching PubMed, Embase, and Cochrane library. The randomized controlled trials (RCTs) that ICI monotherapy or ICI plus chemotherapy compared with chemotherapy in NSCLC were included with available primary endpoints of progression‐free survival (PFS), overall survival (OS), objective response rate, or treatment‐related adverse events. A fixed‐effect or random‐effects model was adopted depending on between‐study heterogeneity. RESULTS: A total of 20 RCTs involving 12,025 patients with NSCLC were included. Both ICI‐monotherapy and ICI‐chemotherapy resulted in significantly prolonged survival compared to chemotherapy and the former led to significantly longer PFS. The magnitude of survival benefits appeared to be greatest among those treated with pembrolizumab plus platinum‐based chemotherapy (OS, 0.56; PFS, 0.54). Additionally, OS and PFS advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD‐L1) expression level, but not in intermediate PD‐L1 TPS. CONCLUSIONS: Pembrolizumab plus platinum‐based chemotherapy was recommended as the optimal first‐line therapy for advanced patients with NSCLC. Additionally, PD‐L1 alone is not recommended as an adequate molecular biomarker to identify eligible patients for routine clinical practice in immunotherapy. John Wiley and Sons Inc. 2019-11-06 2020-05 /pmc/articles/PMC7028135/ /pubmed/31693178 http://dx.doi.org/10.1002/jcp.29371 Text en © 2019 The Authors. Journal of Cellular Physiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Articles Wang, Chengdi Qiao, Wenliang Jiang, Yuting Zhu, Min Shao, Jun Wang, Tao Liu, Dan Li, Weimin The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title | The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title_full | The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title_fullStr | The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title_full_unstemmed | The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title_short | The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis |
title_sort | landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: a systematic review and meta‐analysis |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/ https://www.ncbi.nlm.nih.gov/pubmed/31693178 http://dx.doi.org/10.1002/jcp.29371 |
work_keys_str_mv | AT wangchengdi thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT qiaowenliang thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT jiangyuting thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhumin thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT shaojun thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT wangtao thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT liudan thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT liweimin thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT wangchengdi landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT qiaowenliang landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT jiangyuting landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhumin landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT shaojun landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT wangtao landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT liudan landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT liweimin landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis |